Please login to the form below

Not currently logged in


This page shows the latest ophthalmology news and features for those working in and with pharma, biotech and healthcare.

Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture

Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture

Biogen said the new licensing deal continues its expansion into ophthalmology through the recent $800m acquisition of gene therapy specialist  Nightstar Therapeutics.

Latest news

More from news
Approximately 8 fully matching, plus 100 partially matching documents found.

Latest Intelligence

  • Diagnosed Anywhere Diagnosed Anywhere

    The diagnostic report includes treatment advice aligned with the American Academy of Ophthalmology’s preferred practice pattern for diabetic retinopathy.

  • Deal Watch October 2018

    Sandoz’s US business has retained its biosimilars, value‐added medicines and complex generics, including the ophthalmology products.

  • Deal Watch January 2018

    Collaboration, licence. 830. Molecular Partners/ Allergan. Option exercise for 2 DARPins from Allergan's ophthalmology alliance signed in 2012.

  • The good, the bad and the ugly The good, the bad and the ugly

    Ophthalmology. Ophthalmology is dominated by a small number of the same therapies marketed by different companies in different regions; Regeneron, Bayer and Santen all market Eylea, whereas Novartis and Roche market ... Biogen was the largest seller in

  • Deal Watch - May 2017 Deal Watch - May 2017

    products with a focus on ophthalmology will cost $4.75bn representing 12 x EBITDA.  Since 2013 Akorn has been on a spending spree buying US rights to timolol and other ophthalmics

More from intelligence
Approximately 2 fully matching, plus 19 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 28 partially matching documents found.

Latest from PMHub

  • emotive adds to medical team with new Scientific Lead and Associate Medical Writer

    Kate is experienced in a wide range of therapy areas, including immunology, specifically Crohn’s disease, ulcerative colitis and psoriatic arthritis, in ophthalmology, including retinal diseases, glaucoma and dry eye disease,

  • Wilmington Healthcare appoints new Account Director

    His final post at the company was Brand Lead, Ophthalmology.  Before joining Novartis, Gareth held senior sales and product manager positions at Gilead Sciences Ltd in their anti-infective franchise.

  • Leading Edge bolsters its delivery team

    ophthalmology, cardiovascular disease and neuroscience. "I enjoy working with both patients and healthcare professionals, to really get to understand their challenges and provide solutions that ultimately lead to improved outcomes", she

  • Hayward Medical Communications launch a new, eye-opening journal

    Ophthalmology in practice will also feature case studies, patient viewpoints, and service development and guidance updates. ... Ophthalmology in practice is a free resource for healthcare professionals in the UK.

  • Unlimited wins at Communiqué Awards

    with Bayer plc won the award for Excellence in Corporate Communications – External Stakeholders for their Bayer Ophthalmology Honours programme which recognises and showcases the very best ophthalmology care in the UK ... and was launched in 2015 to

More from PMHub
Approximately 1 fully matching, plus 13 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...
Precision medicine at Blue Latitude Health
At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and...
Understanding the evolving CAR-T market
In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in...